Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data From The Ongoing Phase 1 Study Of ELI-002 And New Preclinical Data On ELI-007 And ELI-008 At The Society For Immunotherapy Of Cancer Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics (NASDAQ:ELTX) has presented updated preliminary data from its ongoing Phase 1 study of ELI-002, a therapeutic cancer vaccine, and new preclinical data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer Annual Meeting. The data shows promising results in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers. The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death. ELI-007 and ELI-008 also demonstrated strong induction of tumor-antigen-specific T cell responses in mice.
November 03, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics' ongoing Phase 1 study of ELI-002 and new preclinical data on ELI-007 and ELI-008 show promising results in reducing the risk of relapse and death in cancer patients. This could potentially boost the company's stock in the short term.
The promising results from Elicio Therapeutics' ongoing Phase 1 study of ELI-002 and new preclinical data on ELI-007 and ELI-008 could potentially attract more investors, leading to an increase in the company's stock price. The strength of the induced T cell response, which correlated with a significantly reduced risk of relapse and death, is a significant breakthrough in cancer treatment. This could potentially boost the company's reputation and increase investor confidence.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100